New Molecular Target Found for Deadly Complication of Heart Failure
Scientists identify GPRASP1 as a key guardian of pulmonary vascular health, opening a potential drug target for PH-HFpEF.
Summary
Researchers discovered that a protein called GPRASP1 plays a critical role in protecting the lungs' blood vessels in a dangerous form of heart failure. When GPRASP1 is lost from endothelial cells lining pulmonary vessels, it triggers a chain reaction: a metabolic enzyme called ASNS accumulates, disrupting how cells use aspartate — an amino acid central to energy production. This leads to energy depletion, oxidative stress, and loss of nitric oxide, causing pulmonary hypertension. Remarkably, an existing antihistamine drug called olopatadine, which inhibits ASNS, reversed these effects in animal models. This research identifies a new druggable pathway in a condition that currently has no targeted therapies, offering real hope for patients with heart failure with preserved ejection fraction complicated by pulmonary hypertension.
Detailed Summary
Heart failure with preserved ejection fraction (HFpEF) is one of the most common and difficult-to-treat forms of heart failure, and when it is complicated by pulmonary hypertension (PH), outcomes become significantly worse. Despite the clinical urgency, no targeted therapies exist for PH-HFpEF. This study, published in Circulation, identifies a previously unrecognized molecular mechanism driving this condition and points toward a potential therapeutic strategy.
Using transcriptome profiling of pulmonary endothelial cells from PH-HFpEF models, researchers found that GPRASP1 — a protein previously known only for its role in sorting G protein-coupled receptors — was markedly reduced. To test its functional importance, they generated mice with endothelial-specific deletion of GPRASP1, which spontaneously developed hallmark features of PH-HFpEF including elevated pulmonary pressures, vascular remodeling, and diastolic dysfunction.
Mechanistically, GPRASP1 normally acts as a scaffold that recruits the E3 ubiquitin ligase Parkin (PRKN) to tag the enzyme ASNS for proteasomal degradation. Without GPRASP1, ASNS accumulates and diverts aspartate away from the TCA cycle toward asparagine synthesis, starving mitochondria of oxaloacetate. The downstream consequences include ATP depletion, reactive oxygen species buildup, eNOS uncoupling, and nitric oxide deficiency — a perfect storm for endothelial dysfunction and vascular disease.
Critically, the team showed that pharmacological inhibition of ASNS using olopatadine, an FDA-approved antihistamine with off-target ASNS-inhibitory activity, restored normal aspartate metabolism, improved mitochondrial function, and reversed cardiopulmonary pathology in preclinical models.
These findings are significant for clinicians managing HFpEF patients with pulmonary complications. The identification of the GPRASP1-PRKN-ASNS axis as a druggable vulnerability offers a concrete mechanistic rationale for future clinical investigation. Caveats include the preclinical nature of the data and reliance on abstract-only information for this summary.
Key Findings
- GPRASP1 loss in pulmonary endothelial cells drives PH-HFpEF by disrupting aspartate metabolism and mitochondrial energy production.
- GPRASP1 acts as a noncanonical scaffold recruiting Parkin to degrade ASNS, a newly identified disease-relevant enzyme.
- ASNS accumulation diverts aspartate from the TCA cycle, causing ATP depletion, oxidative stress, and nitric oxide deficiency.
- Olopatadine, an existing antihistamine, inhibits ASNS and reverses cardiopulmonary pathology in preclinical PH-HFpEF models.
- GPRASP1 also enhances Parkin-mediated mitophagy under mitochondrial stress, adding a second protective mechanism.
Methodology
The study used transcriptome profiling, endothelial-specific GPRASP1 knockout mouse models, multimodal metabolomics, isotope tracing, and proteomics to map the GPRASP1-PRKN-ASNS pathway. Mechanistic biochemical assays confirmed ubiquitination linkages and protein interactions. Pharmacological rescue experiments used olopatadine to validate ASNS as a therapeutic target.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, which limits assessment of methodology and data quality. All efficacy data are from preclinical mouse models, and translation to human PH-HFpEF remains unproven. The clinical use of olopatadine for this indication would require dedicated safety and efficacy trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.